RocheDiabetes
Care Platform

Roche

Data Privacy & Security



John Michael Smith
ID: 0000000

DATE OF BIRTH: 22 Jan 1970 (50)
DIABETES: Type 1
DIAGNOSIS: Oct 2001

TIME PERIOD: 28 Days
Wed, 1 Apr → Tue, 28 Apr

Dr. Oliver Lister

GLUCOSE LEVEL DISTRIBUTION

Target Range	70 -160 mg/dL
● Above	48.6%
● Within	41.4%
● Below	12.7%
● Hypoglycaemia	9.9%

STATUS

● Low Hypo Risk	60 mg/dL
● Mean Blood Glucose Above Target Range (Target Range: 70-160 mg/dL)	5 mg/dL
● Moderate Variability	60 mg/dL

Roche considers security and privacy of customer data a priority. We apply strict measures and controls to protect the data of healthcare institutions and their patients.

Secure storage

All medical and personal data is stored securely in ISO 27001 compliant data centres. **The infrastructure is HITRUST certified and it is on the Amazon Web Services Cloud** which includes **physical security measures** such as fencing, walls, security staff, video surveillance, intrusion detection, access control systems, etc., and **digital security measures** such as ID authentication, automatic blocking/locking mechanisms, data encryption, multiple authorisation levels, minimum passwords requirements, VPN connections, etc., **based on Roche security standards.** A logging system is in place to ensure that **the actions performed are traceable** and that the audit trails are kept.

Continuous security process

Roche has implemented a multidimensional defence strategy for enhanced data protection and management.

- **Privacy by Design:** Prominent data-protection principles, such as data minimisation and encryption of data are followed as Roche is committed to continuously maintain and enhance data security and privacy.
- **Privacy by Default:** Only necessary personal data as per a specific purpose is processed and it involves the amount of personal data collected, the extent of the respective processing and the period of its storage and accessibility.
- **Availability Control:** All data is protected against accidental and/or unauthorised destruction as appropriate backup processes and respective business contingency plans are in place.
- **Third Party Management:** Roche executes strict controls while selecting external service providers and ensures that proper contractual arrangements and supervisory follow-up checks are in place.

Vulnerability management

Continuous monitoring and threat analysis procedures, for countering new vulnerabilities and security threats for the RocheDiabetes Care Platform. These include:

- **Proactive Data Protection:** Internal and external penetration tests and corresponding assessments and evaluations are regularly performed.
- **Incident Response Management:** Roche applications and underlying infrastructure is constantly monitored, to detect security events or potential incidents.
- **Patch Management:** Security patch management is implemented to provide regular and periodic deployment of relevant security updates.

Secure transmissions

- **Data Transfer Control:** All data communications for the RocheDiabetes Care Platform via Internet are secured by using SSL over the HTTP protocol. Roche credentials and access rights are required to be able to connect through VPN connections.
- **Data Entry Control:** Roche has implemented a logging system for input, modification and deletion of data. Authorisation controls are also in place, so the validation verifies that each logged in user is entitled to perform an action in the system.

Pseudonymisation and encryption

All collected clinical medical data are properly pseudonymised, encrypted and stored in a separate database than the specific Data Subject Identifiable Data. Clinical and non-clinical databases are linked to each user through an individually assigned ID.

The power to personalise care

For more information
RocheDiabetes.co.uk/CarePlatform   *RocheDiabetes.ie/CarePlatform*

| Roche Diabetes Care Limited. Charles Avenue, Burgess Hill, West Sussex, RH15 9RY, UK | Company Registration Number: 09055599
Date of preparation: April 2022 | DMS2022-UK&I-282 | For healthcare professional use only in the UK and Ireland. Not for distribution | All names and data shown have been created for demonstration purposes only and do not relate to a real-life patient. The screens or data you see may differ from the screens in the app. This may include time format and units of measurement, (mmol/L or mg/dL) for example.